Suits Against ICN to Be Tried in N.Y.
- Share via
Several class-action shareholder lawsuits filed in Southland courts against ICN Pharmaceuticals Inc. will be tried in New York to consolidate court action against the embattled Costa Mesa company.
The suits allege that ICN and its Viratek Inc. subsidiary wrongly “hyped” the value of the experimental antiviral drug “Virazole” and accuse ICN, Viratek and a second subsidiary, SPI Pharmaceutical Inc., as well as PaineWebber Inc. and eight ICN officers and directors of securities fraud.
U.S. District Judge Terry J. Hatter Jr. on Monday granted the change of venue at the request of the defendants. According to an attorney for ICN, the motion sought the change of venue because “essentially the same litigation is pending and is further advanced” in the U.S. District Court in New York.
Attorneys for the shareholders could not be reached for comment.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.